Nusinersen—the first FDA-approved drug for the treatment of SMА—is an antisense oligonucleotide that increases SMN expression through modulation of SMN2 pre-mRNA splicing and is administered intrathecally at regular intervals after an initial loading phase8–10. Here, SMN2 is linked to systemic mastocytosis.